Heirloom Wealth Management grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 1.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,608 shares of the pharmaceutical company’s stock after acquiring an additional 321 shares during the quarter. Vertex Pharmaceuticals comprises approximately 2.6% of Heirloom Wealth Management’s portfolio, making the stock its 15th biggest holding. Heirloom Wealth Management’s holdings in Vertex Pharmaceuticals were worth $8,189,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also made changes to their positions in the stock. GHP Investment Advisors Inc. purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $29,000. Annapolis Financial Services LLC purchased a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at $27,000. Stephens Consulting LLC acquired a new position in Vertex Pharmaceuticals in the second quarter valued at $31,000. Founders Capital Management increased its stake in Vertex Pharmaceuticals by 50.0% in the second quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 25 shares during the last quarter. Finally, ZRC Wealth Management LLC purchased a new position in Vertex Pharmaceuticals during the first quarter worth about $39,000. Institutional investors and hedge funds own 90.96% of the company’s stock.
Insider Buying and Selling
In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $20,320,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,487 shares of company stock worth $14,657,149. Insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on VRTX
Vertex Pharmaceuticals Stock Up 2.4 %
Shares of Vertex Pharmaceuticals stock opened at $498.73 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The company has a market capitalization of $128.72 billion, a PE ratio of -245.68 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. The business has a 50-day moving average of $474.92 and a 200-day moving average of $459.08.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same quarter last year, the business earned $3.53 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 6.1% compared to the same quarter last year. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Insider Selling is not a Signal to Start Selling Gartner Stock
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.